糖尿病新世界
糖尿病新世界
당뇨병신세계
DIABETES NEW WORLD
2014年
11期
3-4,6
,共3页
2型糖尿病%甘精胰岛素%慢性肾脏疾病
2型糖尿病%甘精胰島素%慢性腎髒疾病
2형당뇨병%감정이도소%만성신장질병
Type 2 diabetes%Insulin glargine%Chronic kidney disease
目的：探讨对2型糖尿病合并慢性肾脏疾病患者采用甘精胰岛素治疗，探讨和分析其治疗的临床效果。方法将该院2012年10月—2013年12月期间所收治的55例2型糖尿病合并慢性肾脏疾病患者，按照随机数字表法分组为观察组(30例)和对照组(25例)；治疗前，观察组和对照组患者24 h内的血糖平均浓度分别为(13.7±5.7)mmol/L、(13.4±6.0)mmol/L；对照组：采用中性低精蛋白锌人胰岛素进行治疗，可进食的患者，餐前追加短效胰岛素，将血糖浓度控制在5.0~8.0 mmol/L范围内；观察组：在对照组治疗基础上采用甘精胰岛素治疗。结果经过治疗后，观察组和对照组在1、3、5d的平均血糖浓度分别为(11.9±4.8)mmol/L、(7.4±1.3)mmol/L、(5.6±0.7)mmol/L；(13.5±5.6)mmol/L、(10.7±1.9)mmol/L、(6.5±0.8)mmol/L(P<0.05)。但是，两组患者在治疗7 d后的平均血糖浓度进行比较(P>0.05)。结论在临床上，对2型糖尿病合并慢性肾脏疾病患者采用甘精胰岛素进行治疗，有效地控制患者的血糖水平，减轻患者痛苦，改善其临床症状，提高患者生活质量。
目的：探討對2型糖尿病閤併慢性腎髒疾病患者採用甘精胰島素治療，探討和分析其治療的臨床效果。方法將該院2012年10月—2013年12月期間所收治的55例2型糖尿病閤併慢性腎髒疾病患者，按照隨機數字錶法分組為觀察組(30例)和對照組(25例)；治療前，觀察組和對照組患者24 h內的血糖平均濃度分彆為(13.7±5.7)mmol/L、(13.4±6.0)mmol/L；對照組：採用中性低精蛋白鋅人胰島素進行治療，可進食的患者，餐前追加短效胰島素，將血糖濃度控製在5.0~8.0 mmol/L範圍內；觀察組：在對照組治療基礎上採用甘精胰島素治療。結果經過治療後，觀察組和對照組在1、3、5d的平均血糖濃度分彆為(11.9±4.8)mmol/L、(7.4±1.3)mmol/L、(5.6±0.7)mmol/L；(13.5±5.6)mmol/L、(10.7±1.9)mmol/L、(6.5±0.8)mmol/L(P<0.05)。但是，兩組患者在治療7 d後的平均血糖濃度進行比較(P>0.05)。結論在臨床上，對2型糖尿病閤併慢性腎髒疾病患者採用甘精胰島素進行治療，有效地控製患者的血糖水平，減輕患者痛苦，改善其臨床癥狀，提高患者生活質量。
목적：탐토대2형당뇨병합병만성신장질병환자채용감정이도소치료，탐토화분석기치료적림상효과。방법장해원2012년10월—2013년12월기간소수치적55례2형당뇨병합병만성신장질병환자，안조수궤수자표법분조위관찰조(30례)화대조조(25례)；치료전，관찰조화대조조환자24 h내적혈당평균농도분별위(13.7±5.7)mmol/L、(13.4±6.0)mmol/L；대조조：채용중성저정단백자인이도소진행치료，가진식적환자，찬전추가단효이도소，장혈당농도공제재5.0~8.0 mmol/L범위내；관찰조：재대조조치료기출상채용감정이도소치료。결과경과치료후，관찰조화대조조재1、3、5d적평균혈당농도분별위(11.9±4.8)mmol/L、(7.4±1.3)mmol/L、(5.6±0.7)mmol/L；(13.5±5.6)mmol/L、(10.7±1.9)mmol/L、(6.5±0.8)mmol/L(P<0.05)。단시，량조환자재치료7 d후적평균혈당농도진행비교(P>0.05)。결론재림상상，대2형당뇨병합병만성신장질병환자채용감정이도소진행치료，유효지공제환자적혈당수평，감경환자통고，개선기림상증상，제고환자생활질량。
Objective To study and analyze the clinical effect of insulin glargine in the treatment of type 2 diabetes complicated by chronic kidney disease. Methods 55 patients with type 2 diabetes complicated by chronic kidney disease admitted in our hos-pital were grouped into the observation group (30 cases) and control group (25 cases) according to the random number table. Before treatment, the average blood glucose concentration within 24h of the observation group and the control group was(13.7±5.7)mmol/L, (13.4 ±6.0)mmol/L, respectively. For patients in the control group, human insulin isophane was given to them for treatment, and short-acting insulin was also given to the patients who were able to eat before meals for controlling the blood glucose concentration within the range of 5.0~8.0 mmol/L. And for patients in the observation group, insulin glargine was given to them on the basis of the treatment given to the control group. Results The average blood glucose concentration of the observation group and the control group 1, 3, 5d after treatment was (11.9±4.8) mmol/L, (7.4±1.3) mmol/L, (5.6±0.7) mmol/L;(13.5±5.6) mmol/L, (10.7±1.9) mmol/L, (6.5±0.8) mmol/L, respectively (P<0.05). However, the difference in the average blood glucose concentration 7d after treatment be-tween the two groups was not statistically significant (P>0.05). Conclusion For patients with type 2 diabetes complicated by chron-ic kidney disease clinically, insulin glargine can effectively control the blood glucose level, alleviate the pain, improve the clinical symptoms, and enhance the quality of life of the patients.
